Journal
Journal of Clinical Oncology
Publication Date
2-10-2023
Volume
41
Issue
5
First Page
1105
Last Page
1115
Document Type
Open Access Publication
DOI
10.1200/JCO.22.00739
Rights and Permissions
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Camidge, D Ross; Morgensztern, Daniel; and et al., "Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer." Journal of Clinical Oncology. 41, 5. 1105 - 1115. (2023).
https://digitalcommons.wustl.edu/oa_4/1297
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
